[1]. [1]Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16. MEDLINE
[2]. [2]El Sayed NM, Gomatos PJ, Rodier GR, et al. Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus, human immunodeficiency virus and Treponema pallidum infections: association of hepatitis C virus infections with specific regions of Egypt. Am J Trop Med Hyg. 1996;55(2):179–184. MEDLINE
[3]. [3]Abdel Wahab MF, Zakaria S, Kamel M, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg. 1994;51(5):563–567. MEDLINE
[4]. [4]Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl. 1):9–16. Abstract |
Full-Text PDF (917 KB)
|
CrossRef
[5]. [5]Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21(6):1135–1139. MEDLINE |
CrossRef
[6]. [6]Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592–599. MEDLINE
[7]. [7]El Zayadi AR, Selim OE, Hamdy H, et al. Association of chronic hepatitis C infection and diabetes mellitus. Trop Gastroenterol. 1998;19(4):141–144.
[8]. [8]Grimbert S, Valensi P, Levy Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol. 1996;20(6–7):544–548. MEDLINE
[9]. [9]Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113(12):909–915. MEDLINE
[10]. [10]Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic Cohort of women: the women’s health initiative observational study. Diabetes Care. 2007;30(7):1747–1752.
CrossRef
[11]. [11]Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology. 2002;36(3):729–736. MEDLINE |
CrossRef
[12]. [12]Czaja AJ, Carpenter HA, Santrach PJ, et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29(2):198–206. Abstract |
Full-Text PDF (106 KB)
|
CrossRef
[13]. [13]Ratziu V, Munteanu M, Charlotte F, et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. 2003;39(6):1049–1055. Abstract | Full Text |
Full-Text PDF (122 KB)
|
CrossRef
[14]. [14]Martinot Peignoux M, Boyer N, Cazals Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001;34(5):1000–1005. MEDLINE |
CrossRef
[15]. [15]Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2192. MEDLINE |
CrossRef
[16]. [16]Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125(6):1695–1704. Abstract | Full Text |
Full-Text PDF (137 KB)
|
CrossRef
[17]. [17]Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–S53.
[18]. [18]Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet. 1997;349(9055):825–832. Abstract | Full Text |
Full-Text PDF (67 KB)
|
CrossRef
[19]. [19]Puoti C, Magrini A, Stati T, et al. Clinical, histological and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26(6):1393–1398. MEDLINE |
CrossRef
[20]. [20]Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14(10):1521–1528. MEDLINE
[21]. [21]Fehrenbach H, Weiskirchen R, Kasper M, et al. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology. 2001;34(5):943–952. MEDLINE |
CrossRef
[22]. [22]Fukui M, Kitagawa Y, Nakamura N, et al. Response to oncul: Insulin sensitivity in patients with chronic hepatitis C virus infection. Diabetes Care. 2002;25(10):1900-1–1901-2.
[23]. [23]Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003;18(12):1358–1363. MEDLINE |
CrossRef
[24]. [24]El Sammak M, Refai W, El Sawaf A, et al. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin. 2005;21(4):527–534. MEDLINE |
CrossRef
[25]. [25]Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepatol. 2007;14(9):600–607.
[26]. [26]Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus Down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–1508. MEDLINE
[27]. [27]Hui CK, Belaye T, Montegrande K, et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol. 2003;38(4):511–517. Abstract | Full Text |
Full-Text PDF (156 KB)
|
CrossRef
[28]. [28]Fartoux L, Poujol Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003–1008. MEDLINE |
CrossRef
[29]. [29]Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34(4 Pt 1):738–744. MEDLINE |
CrossRef
[30]. [30]D’Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100(7):1509–1515. MEDLINE |
CrossRef